AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32161233 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX 0.12% mouthrinse (twice daily, 10 mL rinse for 30 s)
Number of subjects: 354
Study 32161233 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX 0.20% mouthrinse (twice daily, 10 mL rinse for 30 s)
Number of subjects: 354
Study 32161233 — intervention group
Group type: COMPARATOR
Intervention: No topical treatment (Control group)
Number of subjects: 354
Study 35976200 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving Stories program
Number of subjects: 185
Study 35976200 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 185
Study 32200009 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined bleaching (CB) treatment
Number of subjects: 105
Study 32200009 — intervention group
Group type: COMPARATOR
Intervention: Home bleaching (HB)
Number of subjects: 105
Study 32200009 — intervention group
Group type: COMPARATOR
Intervention: In-office bleaching (IOB)
Number of subjects: 105
Study 32200009 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined bleaching (CB) and In-office bleaching (IOB)
Number of subjects: 105
Study 32200009 — intervention group
Group type: EXPERIMENTAL
Intervention: All bleaching protocols
Number of subjects: 105
Study 35183806 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored open lung approach (OLA)
Number of subjects: 32
Study 35183806 — intervention group
Group type: EXPERIMENTAL
Intervention: End inspiratory pause (EIP) of 30%
Number of subjects: 32
Study 35183806 — intervention group
Group type: COMPARATOR
Intervention: End inspiratory pause (EIP) of 10%
Number of subjects: 32
Study 33663264 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil
Number of subjects: 161
Study 33583390 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-based therapy
Number of subjects: 110
Study 33583390 — intervention group
Group type: COMPARATOR
Intervention: Silymarin therapy
Number of subjects: 110
Study 35137022 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological interventions to optimize treatment expectations (IA group, n = 30)
Number of subjects: 88
Study 35137022 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention (IB group, n = 29) with psychological interventions plus additional treatment package
Number of subjects: 88
Study 35137022 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (SMC, n = 29)
Number of subjects: 88
Study 33689512 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: 110 kV, 80 mA (enhanced cranial mode)
Number of subjects: 18
Study 33689512 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: 120 kV, 64 mA (lumbar spine mode)
Number of subjects: 18
Study 33689512 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: 120 kV, 25 mA (head/neck settings)
Number of subjects: 18
Study 32333208 — intervention group
Group type: EXPERIMENTAL
Intervention: MARTAS (n=135)
Number of subjects: 274
Study 32333208 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) (n=139)
Number of subjects: 274
Study 35484674 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching subgroup
Number of subjects: 24
Study 35484674 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined subgroup
Number of subjects: 24
Study 35484674 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin subgroup
Number of subjects: 24
Study 35484674 — intervention group
Group type: COMPARATOR
Intervention: Control subgroup
Number of subjects: 24
Study 34559005 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated CT lung screening viewer
Number of subjects: 160
Study 34559005 — intervention group
Group type: COMPARATOR
Intervention: Standard PACS-like viewer
Number of subjects: 160
Study 35501082 — intervention group
Group type: EXPERIMENTAL
Intervention: Antianaerobic antibiotics
Number of subjects: 0
Study 34515439 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline enemas twice daily until normal stooling pattern achieved (Group 1)
Number of subjects: 67
Study 34515439 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin and enemas (Group 2)
Number of subjects: 67
Study 34515439 — intervention group
Group type: COMPARATOR
Intervention: Enemas only when symptoms observed (Group 3)
Number of subjects: 67
Study 34515439 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 67
Study 33725465 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 80% V̇O2max
Number of subjects: 21
Study 33725465 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 70% V̇O2max
Number of subjects: 21
Study 33725465 — intervention group
Group type: COMPARATOR
Intervention: Running at 70% V̇O2max
Number of subjects: 21
Study 33725465 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 21
Study 33725465 — intervention group
Group type: COMPARATOR
Intervention: Cycling vs Running
Number of subjects: 21
Study 32888740 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent vaccine (Quinvaxem)
Number of subjects: 0
Study 32888740 — intervention group
Group type: COMPARATOR
Intervention: Hexavalent vaccine (Infanrix-hexa)
Number of subjects: 0
Study 32888740 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent vaccine (Quinvaxem) among TT-vaccinated mothers
Number of subjects: 0
Study 32888740 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary and booster vaccination
Number of subjects: 0
Study 34529839 — intervention group
Group type: EXPERIMENTAL
Intervention: Esflurbiprofen plaster (SFPP)
Number of subjects: 38
Study 34529839 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen tablets (FPT)
Number of subjects: 38
Study 32115598 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized intervention providing repeated data feedback via email to volunteers
Number of subjects: 46
Study 32115598 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 46
Study 35108339 — intervention group
Group type: EXPERIMENTAL
Intervention: PfRAS immunization
Number of subjects: 0
Study 32694328 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator training sessions (TraumaVision Virtual Reality Simulator)
Number of subjects: 28
Study 32694328 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional simulator training)
Number of subjects: 28
Study 35009908 — intervention group
Group type: EXPERIMENTAL
Intervention: Harvard test
Number of subjects: 139
Study 35009908 — intervention group
Group type: COMPARATOR
Intervention: No effort (Control Group Y)
Number of subjects: 139
Study 32106963 — intervention group
Group type: EXPERIMENTAL
Intervention: MyHEARTSMAP self-assessment tool
Number of subjects: 795
Study 34424021 — intervention group
Group type: EXPERIMENTAL
Intervention: If-then plans (behavioral intervention)
Number of subjects: 0
Study 34424021 — intervention group
Group type: COMPARATOR
Intervention: CDC guidelines (control condition)
Number of subjects: 0
Study 32385508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous delta-9-tetrahydrocannabinol (THC)
Number of subjects: 400
Study 35153517 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexDex™
Number of subjects: 40
Study 35153517 — intervention group
Group type: COMPARATOR
Intervention: Traditional rigid needle holder
Number of subjects: 40
Study 33177437 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone
Number of subjects: 22
Study 33177437 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 22
Study 33177437 — intervention group
Group type: EXPERIMENTAL
Intervention: Study treatments (both interventions)
Number of subjects: 22
Study 34959253 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/daily)
Number of subjects: 26
Study 34959253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 34485058 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 41
Study 34485058 — intervention group
Group type: COMPARATOR
Intervention: Office visit
Number of subjects: 41
Study 33025843 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Hyperthermia
Number of subjects: 200
Study 33025843 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 200
Study 36188104 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 73
Study 36188104 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control group)
Number of subjects: 73
Study 33631065 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled interleukin-6 receptor antagonists (tocilizumab and sarilumab)
Number of subjects: 803
Study 32867199 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation (2.6 g EPA and 1.8 g DHA)
Number of subjects: 30
Study 32867199 — intervention group
Group type: COMPARATOR
Intervention: SRP alone (Control)
Number of subjects: 30
Study 36429912 — intervention group
Group type: EXPERIMENTAL
Intervention: Mountainous setting (5-7 days stay, 600-900 m altitude)
Number of subjects: 14
Study 36429912 — intervention group
Group type: COMPARATOR
Intervention: Urban setting
Number of subjects: 14
Study 36429912 — intervention group
Group type: EXPERIMENTAL
Intervention: Mountainous setting
Number of subjects: 14
Study 34107031 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH + WM (Dietary Approaches to Stop Hypertension diet plus behavioral weight management)
Number of subjects: 144
Study 34107031 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH (Dietary Approaches to Stop Hypertension diet)
Number of subjects: 144
Study 34107031 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 144
Study 32409504 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients with diabetes
Number of subjects: 153
Study 32409504 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 patients without diabetes (control)
Number of subjects: 153
Study 35441573 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 60
Study 35441573 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture and colour enhancement imaging (TXI)
Number of subjects: 60
Study 35441573 — intervention group
Group type: COMPARATOR
Intervention: White-light imaging (WLI)
Number of subjects: 60
Study 35509125 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin block (D-group)
Number of subjects: 42
Study 35509125 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone block (A-group)
Number of subjects: 42
Study 33879487 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based pathway for identifying and supporting child anxiety difficulties, including screening and feedback to parents.
Number of subjects: 0
Study 33879487 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from parents, children, and school staff on their experience with the pathway.
Number of subjects: 0
Study 36113416 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D guiding templates (3DGTs)
Number of subjects: 35
Study 36113416 — intervention group
Group type: COMPARATOR
Intervention: Free-hand technique (FH)
Number of subjects: 35
Study 32755427 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Walking (IW)
Number of subjects: 16
Study 32755427 — intervention group
Group type: COMPARATOR
Intervention: Continuous Walking (CW)
Number of subjects: 16
Study 34541889 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling (DN) intervention group
Number of subjects: 33
Study 34541889 — intervention group
Group type: COMPARATOR
Intervention: Sham dry needling (CG) control group
Number of subjects: 33
Study 32484386 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 14
Study 32484386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 34657137 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat treatment
Number of subjects: 65
Study 34657137 — intervention group
Group type: COMPARATOR
Intervention: Control group (lifestyle modification only)
Number of subjects: 65
Study 34657137 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study 33233857 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood eosinophils (≥8%)
Number of subjects: 376
Study 33233857 — intervention group
Group type: COMPARATOR
Intervention: Low blood eosinophils (<8%)
Number of subjects: 376
Study 33742561 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal oxygen saturation (SatO2) assessment using Oxymap T1
Number of subjects: 41
Study 33673910 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic unexplained GI symptoms over 20 years
Number of subjects: 228
Study 33673910 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom transitions
Number of subjects: 228
Study 33673910 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-GI somatic symptom scores
Number of subjects: 228
Study 33738034 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimbex® (brand name cisatracurium)
Number of subjects: 22
Study 33738034 — intervention group
Group type: COMPARATOR
Intervention: Cisatrex® (generic cisatracurium)
Number of subjects: 22
Study 33561964 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice bran dietary intervention (30 g over 24 hours for 24 weeks)
Number of subjects: 40
Study 33561964 — intervention group
Group type: COMPARATOR
Intervention: Rice powder (control group, 30 g over 24 hours for 24 weeks)
Number of subjects: 40
Study 32186960 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-4 gene rs2243291 genotype (C/G)
Number of subjects: 369
Study 32186960 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-α gene rs3093726 genotype (CT)
Number of subjects: 369
Study 32186960 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-α gene rs1800629 genotype
Number of subjects: 369
Study 32186960 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 gene rs1800896 genotype
Number of subjects: 369
Study 34678863 — intervention group
Group type: EXPERIMENTAL
Intervention: Danzhi Xiaoyao Powder combined with escitalopram oxalate
Number of subjects: 0
Study 34678863 — intervention group
Group type: COMPARATOR
Intervention: Danzhi Xiaoyao Powder simulant combined with citalopram oxalate
Number of subjects: 0
Study 32199509 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine plus CBT
Number of subjects: 439
Study 32199509 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 439
Study 32199509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study 33206894 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical-practical course-workshop (6 months duration)
Number of subjects: 60
Study 33206894 — intervention group
Group type: COMPARATOR
Intervention: Control group (Unit A)
Number of subjects: 60
Study 34526095 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pharmacological treatment with ibuprofen (administered 24-72 hours postnatal age)
Number of subjects: 0
Study 34526095 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 0
Study 34526095 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pharmacological treatment with ibuprofen
Number of subjects: 0
Study 32452128 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (median dose 22.5 mg/day)
Number of subjects: 1767
Study 32452128 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1767
Study 32452128 — intervention group
Group type: COMPARATOR
Intervention: Placebo (median dose 27.5 mg/day)
Number of subjects: 1767
Study 35232809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (TOF) 5 or 10 mg BID
Number of subjects: 0
Study 35232809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (TOF) 5 mg BID
Number of subjects: 0
Study 35232809 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 0
Study 35232809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35232809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (TOF) 5 mg BID with methotrexate (MTX)
Number of subjects: 0
Study 35232809 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA) with MTX
Number of subjects: 0
Study 32712591 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercise and thoracic mobilization with strengthening exercises
Number of subjects: 30
Study 32712591 — intervention group
Group type: COMPARATOR
Intervention: Lumbar stabilization exercises
Number of subjects: 30
Study 35973146 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD&amp;me
Number of subjects: 152
Study 35973146 — intervention group
Group type: COMPARATOR
Intervention: Biologics fact sheet
Number of subjects: 152
Study 34342268 — intervention group
Group type: EXPERIMENTAL
Intervention: APPetite-mobile-app
Number of subjects: 157
Study 34342268 — intervention group
Group type: COMPARATOR
Intervention: APPetite-food record
Number of subjects: 157
Study 34342268 — intervention group
Group type: COMPARATOR
Intervention: 24-hour recall
Number of subjects: 157
Study 32118387 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Exercise (EXE)
Number of subjects: 76
Study 32118387 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary Treatment (INTER)
Number of subjects: 76
Study 34433772 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized opioid tapering plan
Number of subjects: 110
Study 34433772 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 110
Study 32656706 — intervention group
Group type: EXPERIMENTAL
Intervention: New risk model for prognostic prediction after TAVR
Number of subjects: 388
Study 33465342 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prophylactic anticoagulation (either at intermediate or equivalent to therapeutic dose)
Number of subjects: 538
Study 33465342 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 538
Study 33465342 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prophylactic anticoagulation
Number of subjects: 538
Study 33452547 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (PLA plates sterilized using an autoclave program at 134 °C)
Number of subjects: 186
Study 33452547 — intervention group
Group type: COMPARATOR
Intervention: Group B (PLA plates seeded in different culture media)
Number of subjects: 186
Study 33452547 — intervention group
Group type: COMPARATOR
Intervention: Group C (PLA plates used for crystal violet stains on biofilms)
Number of subjects: 186
Study 33950537 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Counselling Group (OCG) - 26 subjects
Number of subjects: 53
Study 33950537 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Group (WLG) - 27 subjects
Number of subjects: 53
Study 33165269 — intervention group
Group type: EXPERIMENTAL
Intervention: Slot-scanning technique
Number of subjects: 194
Study 33165269 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 194
Study 35551374 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-Release Calcifediol (ERC) treatment (60 μg/day) for 8 weeks
Number of subjects: 0
Study 35551374 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol (300,000 IU/month)
Number of subjects: 0
Study 35551374 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-Release Calcifediol (ERC) treatment (30 or 60 μg/day)
Number of subjects: 0
Study 35551374 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 35551374 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D supplements (cholecalciferol or ergocalciferol)
Number of subjects: 0
Study 34127302 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase irrigation (150,000 IU)
Number of subjects: 108
Study 34127302 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase irrigation (50,000 IU)
Number of subjects: 108
Study 34127302 — intervention group
Group type: COMPARATOR
Intervention: Saline irrigation
Number of subjects: 108
Study 32303700 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic agents with different modes of action
Number of subjects: 0
Study 32303700 — intervention group
Group type: COMPARATOR
Intervention: Aminosalicylate therapy
Number of subjects: 0
Study 35845502 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure (SAA) combined with usual care
Number of subjects: 114
Study 35845502 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 114
Study 33292667 — intervention group
Group type: EXPERIMENTAL
Intervention: CREST intervention (7-week cognitive stimulation programme followed by an 8-week physical exercise programme for people with dementia and a 6-week educational programme for caregivers)
Number of subjects: 10
Study 33292667 — intervention group
Group type: EXPERIMENTAL
Intervention: CREST intervention
Number of subjects: 10
Study 35133113 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab self-injection using safety syringe
Number of subjects: 211
Study 35133113 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab self-injection using auto-injector
Number of subjects: 211
Study 35133113 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab self-injection at Baseline (both devices)
Number of subjects: 211
Study 34579796 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS before ECT
Number of subjects: 56
Study 34579796 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS before ECT
Number of subjects: 56
Study 33563233 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based radiomics predictive model
Number of subjects: 132
Study 32470635 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave coronary IVL catheter
Number of subjects: 0
Study 35343723 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Trauma Recovery for Refugees (MBTR-R)
Number of subjects: 158
Study 35343723 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 158
Study 34273680 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD; n = 10)
Number of subjects: 33
Study 34273680 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (HP; n = 10)
Number of subjects: 33
Study 34273680 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet with whey supplementation (HPW; n = 10)
Number of subjects: 33
Study 35593915 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral delta‐9‐tetrahydrocannabinol (THC) 7.5 mg
Number of subjects: 0
Study 35593915 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral delta‐9‐tetrahydrocannabinol (THC) 15 mg
Number of subjects: 0